Skip to main content

Insulin aspart/insulin degludec Pregnancy and Breastfeeding Warnings

Insulin aspart/insulin degludec is also known as: Ryzodeg 70/30

Insulin aspart/insulin degludec Pregnancy Warnings

Animal reproduction studies have not revealed any difference between insulin degludec and human insulin regarding embryotoxicity and teratogenicity. When compared to human insulin, insulin aspart has not shown any adverse effect on pregnancy or on the health of the fetus. Pregnancies complicated by hyperglycemia pose an increased risk of birth defects, pregnancy loss, and other adverse events. The estimated background risk of major birth defects in women with pre-gestational diabetes and a HbA1c greater than 7 has been estimated at 6% to 10% and as high as 20% to 25% in women with a HbA1c greater than 10. Patients with diabetes or a history of gestational diabetes should maintain good metabolic control before conception and during pregnancy. There are no controlled data in human pregnancy..

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Benefit should outweigh risk

AU TGA pregnancy category: B3
US FDA pregnancy category: Not assigned

Risk Summary: There is no data to inform a drug-associated risk for major birth defects and miscarriage; available information from published randomized controlled trials with insulin aspart during the second trimester of pregnancy have not reported an association with major birth defects or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy.

-Intensified blood glucose control and monitoring are recommended throughout pregnancy and when contemplating pregnancy.
-Insulin requirements usually decrease in the first trimester and increase during the second and third trimester. After delivery, insulin requirements generally return rapidly to pre-pregnancy values.

See references

Insulin aspart/insulin degludec Breastfeeding Warnings

Use with caution

Excreted into human milk: Unknown
Excreted into animal milk: Yes

-Breast-feeding mothers may require adjustments in insulin dose.

Animal studies in rats have shown that insulin degludec is present in milk in a concentration that is lower than in plasma. Exogenous insulins, including the newer biosynthetic insulins (i.e. aspart, detemir, glargine, glulisine, lispro) appear to be excreted into human breast milk. Insulin is a protein that is inactivated if taken by mouth. No metabolic effects are expected in the nursing infant. If absorbed, it would be destroyed in the digestive tract of the infant.

Lactation onset occurs later in women with type 1 diabetes, and there is an even greater delay in those with poor glucose control. However, once established lactation persists as long in mothers with diabetes as in mothers without. Insulin requirements are generally lower in women who breastfeed, most likely due to glucose being used for milk production.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc (2015):

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec)." Novo Nordisk Pharmaceuticals Inc (2015):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.